Evidence map›Paper›PMID 37812432›Full record

ArticleJAMA neurology2023

Tau Oligomer-Containing Synapse Elimination by Microglia and Astrocytes in Alzheimer Disease.

Raquel N Taddei, Romain Perbet, Anastasie Mate de Gerando, Anne E Wiedmer, Maria Sanchez-Mico, Theresa Connors Stewart, Angelica Gaona, Alexandra Melloni, Ana C Amaral, Karen Duff and 2 more

Open access · greenAbstract read
In one paragraph

Article in JAMA neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Perisynaptic Astrocytic Processes as Communication Hubs and Early Sites of Dysfunction.The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Neurotransmitter Systems in Alzheimer's Disease.Current issues in molecular biology · 2026
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Raquel N TaddeiNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Romain PerbetNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Anastasie Mate de GerandoNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Anne E WiedmerNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Maria Sanchez-MicoNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Theresa Connors StewartC.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, Massachusetts.
Angelica GaonaC.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, Massachusetts.
Alexandra MelloniC.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, Massachusetts.
Ana C AmaralNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Karen DuffDepartment of Neurology, Dementia Research Institute, University College London, United Kingdom.
Matthew P FroschC.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Boston, Massachusetts.
Teresa Gómez-IslaNeurology Department, Massachusetts General Hospital, Harvard University, Boston, Massachusetts.
Massachusetts General Hospital · USHarvard University · USUK Dementia Research Institute · GB

Funding

The infectious etiology of Alzheimer's disease revealed at nanoscale precisionR56AG069192 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI AN, BOBAE · 2020 to 2020
$1.5M
NIA NIH HHS R56 AG069192
6 · The paper itself

Abstract

Importance: Factors associated with synapse loss beyond amyloid-β plaques and neurofibrillary tangles may more closely correlate with the emergence of cognitive deficits in Alzheimer disease (AD) and be relevant for early therapeutic intervention. Objective: To investigate whether accumulation of tau oligomers in synapses is associated with excessive synapse elimination by microglia or astrocytes and with cognitive outcomes (dementia vs no dementia [hereinafter termed resilient]) of individuals with equal burdens of AD neuropathologic changes at autopsy. Design, Setting, and Participants: This cross-sectional postmortem study included 40 human brains from the Massachusetts Alzheimer Disease Research Center Brain Bank with Braak III to IV stages of tau pathology but divergent antemortem cognition (dementia vs resilient) and cognitively normal controls with negligible AD neuropathologic changes. The visual cortex, a region without tau tangle deposition at Braak III to IV stages, was assessed after expansion microscopy to analyze spatial relationships of synapses with microglia and astrocytes. Participants were matched for age, sex, and apolipoprotein E status. Evidence of Lewy bodies, TDP-43 aggregates, or other lesions different from AD neuropathology were exclusion criteria. Tissue was collected from July 1998 to November 2020, and analyses were conducted from February 1, 2022, through May 31, 2023. Main Outcomes and Measures: Amyloid-β plaques, tau neuropil thread burden, synapse density, tau oligomers in synapses, and internalization of tau oligomer-tagged synapses by microglia and astrocytes were quantitated. Analyses were performed using 1-way analysis of variance for parametric variables and the Kruskal-Wallis test for nonparametric variables; between-group differences were evaluated with Holm-Šídák tests. Results: Of 40 included participants (mean [SD] age at death, 88 [8] years; 21 [52%] male), 19 had early-stage dementia with Braak stages III to IV, 13 had resilient brains with similar Braak stages III to IV, and 8 had no dementia (Braak stages 0-II). Brains with dementia but not resilient brains had substantial loss of presynaptic (43%), postsynaptic (33%), and colocalized mature synaptic elements (38%) compared with controls and significantly higher percentages of mature synapses internalized by IBA1-positive microglia (mean [SD], 13.3% [3.9%] in dementia vs 2.6% [1.9%] in resilient vs 0.9% [0.5%] in control; P < .001) and by GFAP-positive astrocytes (mean [SD], 17.2% [10.9%] in dementia vs 3.7% [4.0%] in resilient vs 2.7% [1.8%] in control; P = .001). In brains with dementia but not in resilient brains, tau oligomers more often colocalized with synapses, and the proportions of tau oligomer-containing synapses inside microglia (mean [SD] for presynapses, mean [SD], 7.4% [1.8%] in dementia vs 5.1% [1.9%] resilient vs 3.7% [0.8%] control; P = .006; and for postsynapses 11.6% [3.6%] dementia vs 6.8% [1.3%] resilient vs 7.4% [2.5%] control; P = .001) and astrocytes (mean [SD] for presynapses, 7.0% [2.1%] dementia vs 4.3% [2.2%] resilient vs 4.0% [0.7%] control; P = .001; and for postsynapses, 7.9% [2.2%] dementia vs 5.3% [1.8%] resilient vs 3.0% [1.5%] control; P < .001) were significantly increased compared with controls. Those changes in brains with dementia occurred in the absence of tau tangle deposition in visual cortex. Conclusion and Relevance: The findings from this cross-sectional study suggest that microglia and astrocytes may excessively engulf synapses in brains of individuals with dementia and that the abnormal presence of tau oligomers in synapses may serve as signals for increased glial-mediated synapse elimination and early loss of brain function in AD.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAstrocytesChildCross-Sectional StudiesFemaleHumansMaleMicrogliaNeurogliaSynapsesAmyloid beta-Peptides

Identifiers

PMID37812432
PMCPMC10562992
OpenAlexW4387440243

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.